SCHEMBL21772602

SCHEMBL21772602

N=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1Cc1cccc(C(=O)N2CCc3ccc(C(F)(F)F)cc3C2)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 1/20 0.44
PARP1 P09874 1/20 0.42
HPGD P15428 3/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NAMPT P43490 2/20 0.40
CYP3A4 P08684 2/20 0.39
CYP2C19 P33261 2/20 0.39
GAA P10253 1/20 0.39
MAPK10 P53779 2/20 0.38
MAPK8 P45983 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
SPR P35270 1/20 0.38
KDM4E B2RXH2 1/20 0.37
LMNA P02545 1/20 0.37
HDAC1 Q13547 1/20 0.37
CHRM5 P08912 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
CYP2D6 P10635 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20332646 0.98 TACR1 (0.45) TACR1PARP1HPGDALDH1A1SMN1; SMN2
SCHEMBL20332362 0.95 TACR1 (0.45) TACR1SMN1; SMN2NAMPTCYP3A4CYP2C19
SCHEMBL7556241 0.90 PARP1 (0.51) PARP1HPGDALDH1A1SMN1; SMN2NAMPT
SCHEMBL20304310 0.90 HPGD (0.51) PARP1HPGDALDH1A1SMN1; SMN2NAMPT
SCHEMBL20332623 0.89 TACR1 (0.40) TACR1ALDH1A1SMN1; SMN2NAMPTCYP3A4
SCHEMBL20304296 0.87 ALDH1A1 (0.49) TACR1PARP1HPGDALDH1A1SMN1; SMN2
SCHEMBL20332680 0.85 TACR1 (0.38) TACR1PARP1HPGDALDH1A1SMN1; SMN2
SCHEMBL20332113 0.84 TRAP1 (0.44) HPGDALDH1A1SMN1; SMN2NAMPTCYP2D6
SCHEMBL20332523 0.84 HPGD (0.46) PARP1HPGDALDH1A1SMN1; SMN2NAMPT
SCHEMBL20304311 0.82 CNR1 (0.41) TACR1PARP1ALDH1A1SMN1; SMN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200069691-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-03-05 US claimed
US-20200069691-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-03-05 US disclosed
US-20200069691-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2020-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200069691-A1 HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS SERPINB1, PREP, PEPD TACR1 1970/4885PARP1 163/4885HPGD 231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.